Axitinib as a third or further line of treatment in renal cancer: a single institution experience

被引:0
作者
G. Tsironis
M. Liontos
A. Kyriazoglou
K. Koutsoukos
A. Tsiara
M. Kaparelou
R. Zakopoulou
A. Cohen
E. Skafida
S. Fontara
F. Zagouri
A. Bamias
M. A. Dimopoulos
机构
[1] Alexandra Hospital,Oncology Unit, Department of Clinical Therapeutics
[2] Aretaieio University hospital,1st Department of Radiology
来源
BMC Urology | / 20卷
关键词
Axitinib;beyond second line; mRCC; Long responders; TKIs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 238 条
  • [1] Zagouri F(2015)Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-urinary Cancer group (HGUCG) Crit Rev Oncol Hematol 93 36-49
  • [2] Peroukidis S(2017)Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation Oncologist 22 667-679
  • [3] Tzannis K(2005)Renal-cell carcinoma N Engl J Med 353 2477-2490
  • [4] Kouloulias V(2017)Renal cell carcinoma: new insights and challenges for a clinician scientist Am J Physiol Renal Physiol 313 F145-F154
  • [5] Bamias A(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
  • [6] Bamias A(2010)Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061-1068
  • [7] Escudier B(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134
  • [8] Sternberg CN(2007)Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-2111
  • [9] Zagouri F(2015)Cabozantinib versus Everolimus in advanced renal-cell carcinoma N Engl J Med 373 1814-1823
  • [10] Dellis A(2008)Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449-456